FY2026 Earnings Estimate for BMY Issued By Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has updated their FY2026 EPS estimate for Bristol Myers Squibb to $6.15 per share, slightly increasing it from $6.06, while maintaining a "Neutral" rating and target price of $55.00.
• Bristol Myers Squibb reported a quarterly earnings per share of $1.46, surpassing analysts' expectations of $1.07, with revenue of $12.27 billion for the quarter.
• The company announced a quarterly dividend of $0.62, representing a yield of 5.2%, with a 100% dividend payout ratio.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for shares of Bristol Myers Squibb in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $6.15 per share for the year, up from their previous estimate of $6.06. Cantor Fitzgerald currently has a "Neutral" rating and a $55.00 target price on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.

BMY has been the topic of several other research reports. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Finally, Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $56.38.

Bristol Myers Squibb Stock Up 1.3%

Shares of NYSE BMY traded up $0.64 during trading hours on Thursday, hitting $48.45. 11,206,898 shares of the stock were exchanged, compared to its average volume of 12,717,643. The company has a market cap of $98.62 billion, a PE ratio of 19.54, a PEG ratio of 2.48 and a beta of 0.36. Bristol Myers Squibb has a 12 month low of $42.96 and a 12 month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The firm has a fifty day moving average price of $47.23 and a 200-day moving average price of $51.45.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb's revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.07 EPS.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.1%. Bristol Myers Squibb's dividend payout ratio is currently 100.00%.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of large investors have recently added to or reduced their stakes in BMY. Mcintyre Freedman & Flynn Investment Advisers Inc. raised its position in shares of Bristol Myers Squibb by 20.0% in the second quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. now owns 6,000 shares of the biopharmaceutical company's stock valued at $278,000 after buying an additional 1,000 shares during the last quarter. Public Sector Pension Investment Board boosted its stake in Bristol Myers Squibb by 42.2% during the second quarter. Public Sector Pension Investment Board now owns 395,335 shares of the biopharmaceutical company's stock worth $18,300,000 after buying an additional 117,242 shares during the period. Headlands Technologies LLC purchased a new position in Bristol Myers Squibb during the second quarter worth about $591,000. CANADA LIFE ASSURANCE Co boosted its stake in Bristol Myers Squibb by 5.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 3,298,880 shares of the biopharmaceutical company's stock worth $152,932,000 after buying an additional 156,658 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in Bristol Myers Squibb by 159.6% during the second quarter. Tower Research Capital LLC TRC now owns 153,958 shares of the biopharmaceutical company's stock worth $7,127,000 after buying an additional 94,647 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.